0.71Open0.71Pre Close0 Volume1 Open Interest360.00Strike Price0.00Turnover75.72%IV42.16%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry0.71Extrinsic Value100Contract SizeAmericanOptions Type0.0395Delta0.0018Gamma357.38Leverage Ratio-0.0892Theta0.0057Rho14.13Eff Leverage0.0537Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet